(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



- 1 LEAR ON COLUMN TO THE COLUMN C

(43) International Publication Date 10 February 2005 (10.02.2005)

PCT

(10) International Publication Number WO 2005/012304 A2

(51) International Patent Classification7: C07D 487/00

(21) International Application Number:

PCT/EP2004/051457

(22) International Filing Date: 12 July 2004 (12.07,2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data: PCT/EP03/50314

16 July 2003 (16.07.2003) RP

(71) Applicant (for all designated States except US): JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turn-houtsoweg 30, B-2340 Beetre (BE).

(72) Inventors: and

- (75) Inventors/Applicants (for US onty): FREYNE, Eddy, Jean, Edgard [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutsweg 30, B-2340 Beerse (BE). LOVE, Christopher, John [GB/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). COOYMANS, Ludwig, Paul [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). VANDER-MAESEN, Nele [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). BUIJN-STERS, Peter, Jacobus, Johannes, Antonius [NL/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). WILLEMS, Marc [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE). EMBRECHTS, Werner, Constant, Johan [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, B-2340 Beerse (BE).
- (74) Common Representative: JANSSEN PHARMACEUTICA N.V.; Turnhoutseweg 30, B-2340 Beerre (BB).


- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EB, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, FL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FL, FR, GB, GR, HII, IB, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, MI., MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

as to applicant's entitlement to apply for und be granted a patent (Rule 4.17(il)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, Fl, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TI, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,

[Continued on next page]

(54) Title: TRIAZOLOPYRIMIDINE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3 INHIBITORS



(57) Abstract: This invention concerns compounds of formula (I) a N-oxide, a pharmaccutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein ring A represents phenyl, pyridyl, pyrimidinyl, pyridazinyl or pyrazinyl; R¹ represents hydrogen; aryl; formyl; C₁₋₆ alkylcarbonyl; C₁

at least one heteroatom selected from 0, S or N; R⁴ represents hydrogen; halo; hydroxy; optionally substituted C₁₋₂alkyl; optionally substituted C₁₋₂alkyloxy; C₁₋₂alkyloxy; polyhaloC₁₋₃alkyloxy; C₁₋₂alkyloxy; polyhaloC₁₋₃alkyloxy; C₁₋₂alkyloxy; polyhaloC₁₋₃alkyloxy; C₁₋₂alkyloxy; C₁₋₂alkyloxy; C₁₋₄alkyloxy; polyhaloC₁₋₄alkyloxy; polyhaloC₁₋₄alkyloxy; C₁₋₄alkyloxy; C₁₋₄alkyloxy; C₁₋₄alkyloxy; polyhaloC₁₋₄alkyloxy; carboxyl; NR⁹R¹⁰; C(=O)NR⁹R¹⁰; -NR⁵-C(=O)-NR⁹R¹⁰; -NR⁵-C(=O)-R⁵; -S(=O)_{n1},-R¹¹-NR⁵-S(=O)_{n1},-R¹¹-S-CN; -NR⁵-CN; their use, pharmaceutical compositions comprising them and processes for their preparation.

IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), QAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

- as to the applicant's entitlement to claim the priority of the sarlier application (Rule 4.17(III)) for all designations
- of inventorship (Rule 4.17(lv)) for US only

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.